8-K: Spero Therapeutics Announces Q1 2025 Results and Business Update; Tebipenem HBr Phase 3 Interim Analysis Expected in Q2

Spero Therapeutics reports Q1 2025 financial results and provides a business update, highlighting the upcoming interim analysis of the Phase 3 PIVOT-PO trial for tebipenem HBr.

Summary

• Spero Therapeutics announced its first quarter 2025 financial results, reporting a net loss of $13.9 million compared to a net loss of $12.7 million in the first quarter of 2024.
• Total revenue for Q1 2025 was $5.9 million, down from $9.3 million in Q1 2024, primarily due to a decrease in grant revenue, partially offset by higher collaboration revenue from GSK.
• Research and development expenses decreased to $13.6 million from $17.3 million year-over-year, mainly due to lower spending on the SPR720 program.
• General and administrative expenses increased to $6.8 million from $5.9 million year-over-year, driven by higher personnel-related costs and consulting fees.
• As of March 31, 2025, Spero had $48.9 million in cash and cash equivalents.
• The company anticipates that its existing cash, along with $23.75 million in milestone payments from GSK, will fund operations into Q2 2026.
• The pre-specified interim analysis of the Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is on track to be completed in Q2 2025.
• Esther Rajavelu was appointed as Spero's President and Chief Executive Officer, effective May 2, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is progressing with its clinical trials and has sufficient funding into Q2 2026, the increased net loss and decreased revenue compared to the previous year are concerning. The suspension of the SPR720 program is also a negative factor.

Positives

• Spero anticipates that its existing cash and cash equivalents, together with upcoming $23.75M of earned and non-contingent development milestone payments from GSK will be sufficient to fund its operating expenses and capital expenditures into Q2 2026.
• The pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), is on track to be completed in Q2 2025.
• Collaboration revenue increased due to the agreement with GSK.

Negatives

• Spero reported a net loss of $13.9 million for the first quarter of 2025, which is higher than the $12.7 million loss in the first quarter of 2024.
• Total revenue for the first quarter of 2025 decreased to $5.9 million from $9.3 million in the first quarter of 2024.
• The oral development program in NTM-PD was suspended in 4Q 2024 after a Phase 2a study did not meet its primary endpoint.

Risks

• The company's future depends on the success of tebipenem HBr, and its development is subject to regulatory delays, patient enrollment challenges, and clinical trial outcomes.
• Spero relies on GSK for the development and commercialization of tebipenem HBr, and GSK has the right to determine whether to continue the PIVOT-PO trial.
• Spero may need additional funding to continue its operations beyond Q2 2026.
• The company faces risks related to commercializing its product candidates and retaining key personnel.

Future Outlook

Spero anticipates that its existing cash and cash equivalents, together with upcoming milestone payments from GSK, will be sufficient to fund its operating expenses and capital expenditures into Q2 2026. The company is focused on the successful execution of the tebipenem HBr clinical program and the upcoming interim analysis of the PIVOT-PO trial.

Management Comments

• At Spero, our top priority remains the successful execution of the tebipenem HBr clinical program as we prepare for the pre-specified interim analysis of the PIVOT-PO trial during the second quarter, said Esther Rajavelu, President and Chief Executive Officer.
• We are developing tebipenem HBr to address the significant unmet need for an oral carbapenem option in the treatment of complicated urinary tract infections.
• We believe that, if approved, tebipenem HBr could deliver meaningful clinical and economic benefits, by improving patient outcomes and reducing the need for hospital stays.

Industry Context

Spero Therapeutics is focused on developing novel treatments for multi-drug resistant bacterial infections, an area of increasing concern in the healthcare industry. The development of tebipenem HBr, an oral carbapenem antibiotic, addresses the need for outpatient treatment options for complicated urinary tract infections, potentially reducing hospital stays and healthcare costs.

Comparison to Industry Standards

• The Phase 3 PIVOT-PO trial compares oral tebipenem HBr with intravenous imipenem-cilastatin, a standard treatment for cUTI/AP.
• If approved, tebipenem HBr would compete with existing IV carbapenems but offer the advantage of oral administration, similar to how oral antibiotics like ciprofloxacin and levofloxacin compete with IV antibiotics for less severe infections.
• Companies like Nabriva Therapeutics (which markets oral antibiotic Xenleta) and Melinta Therapeutics (which markets Baxdela) also target bacterial infections with novel antibiotics, but tebipenem HBr's carbapenem class could offer a different spectrum of activity and resistance profile.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and clinical trial progress will impact shareholder value.
• Employees: The company's financial stability and strategic direction will affect employee job security and opportunities.
• Patients: The development of tebipenem HBr could provide a new treatment option for complicated urinary tract infections.
• GSK: The collaboration with GSK is crucial for the development and commercialization of tebipenem HBr.

Next Steps

• Completion of the pre-specified interim analysis of the Phase 3 PIVOT-PO clinical trial of tebipenem HBr in Q2 2025.
• Analysis of the data from all 25 patients dosed in the Phase 2a proof-of-concept study in NTM-PD to determine next steps for the program.
• Spero's 2025 annual meeting of stockholders, where Esther Rajavelu has been nominated for election to the Board of Directors.

Key Dates

Keywords

Spero Therapeutics, Tebipenem HBr, PIVOT-PO, GSK, Clinical Trial, Financial Results, Q1 2025, cUTI, SPR720